| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8794872 | Ophthalmology Retina | 2017 | 8 Pages |
Abstract
The TREX neovascular AMD management protocol used with ranibizumab in the Treat-and-Extend Protocol in Patients with Wet Age-Related Macular Degeneration (TREX-AMD) study resulted in visual and anatomic gains comparable with those obtained with monthly dosing, and most patients randomized to TREX therapy demonstrated a relatively consistent maximum extension interval.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Charles C. MD, PhD, William C. BS, David M. MD, Daniel E. BA, Rui BA, John F. MD, W. Lloyd MD, Nizar Saleh MD, SriniVas R. MD, TREX-AMD Study Group TREX-AMD Study Group,